Literature DB >> 24964814

Modafinil effects on middle-frequency oscillatory power during rule selection in schizophrenia.

Michael J Minzenberg1, Jong H Yoon2, Yaoan Cheng1, Cameron S Carter3.   

Abstract

Control-related cognitive processes such as rule selection are associated with cortical oscillations in the theta, alpha and, beta ranges, and modulated by catecholamine neurotransmission. Thus, a potential strategy for improving cognitive control deficits in schizophrenia would be to use pro-catecholamine pharmacological agents to augment these control-related oscillations. In a double-blind, placebo-controlled (within-subjects) study, we tested the effects of adjunctive single-dose modafinil 200 mg on rule-related 4-30 Hz oscillations in 23 stable schizophrenia patients, using EEG during cognitive control task performance. EEG data underwent time-frequency decomposition with Morlet wavelets to determine the power of 4-30 Hz oscillations. Modafinil (relative to placebo) enhanced oscillatory power associated with high-control rule selection in theta, alpha, and beta ranges, with modest effects during rule maintenance. Modafinil treatment in schizophrenia augments middle-frequency cortical oscillatory power associated with rule selection, and may subserve diverse subcomponent processes in proactive cognitive control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24964814      PMCID: PMC4229573          DOI: 10.1038/npp.2014.155

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  69 in total

1.  Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons.

Authors:  Sven Kröner; Leonid S Krimer; David A Lewis; Germán Barrionuevo
Journal:  Cereb Cortex       Date:  2006-06-13       Impact factor: 5.357

2.  An information-maximization approach to blind separation and blind deconvolution.

Authors:  A J Bell; T J Sejnowski
Journal:  Neural Comput       Date:  1995-11       Impact factor: 2.026

Review 3.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.

Authors:  Miranda Davies; Lynda Wilton; Saad Shakir
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

Review 5.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

6.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.

Authors:  David A Lewis; Raymond Y Cho; Cameron S Carter; Kevin Eklund; Sarah Forster; Mary Ann Kelly; Debra Montrose
Journal:  Am J Psychiatry       Date:  2008-10-15       Impact factor: 18.112

7.  Induced oscillations and the distributed cortical sources during the Wisconsin card sorting test performance in schizophrenic patients: new clues to neural connectivity.

Authors:  J A González-Hernández; I Cedeño; C Pita-Alcorta; L Galán; E Aubert; P Figueredo-Rodríguez
Journal:  Int J Psychophysiol       Date:  2003-04       Impact factor: 2.997

8.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

Review 9.  Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Authors:  Carlos Saavedra-Velez; Anna Yusim; Deepti Anbarasan; Jean-Pierre Lindenmayer
Journal:  J Clin Psychiatry       Date:  2008-11-18       Impact factor: 4.384

Review 10.  Gain modulation in the central nervous system: where behavior, neurophysiology, and computation meet.

Authors:  E Salinas; T J Sejnowski
Journal:  Neuroscientist       Date:  2001-10       Impact factor: 7.519

View more
  5 in total

1.  A multi-pronged investigation of option generation using depression, PET and modafinil.

Authors:  Yuen-Siang Ang; Cristina Cusin; Yoann Petibon; Daniel G Dillon; Micah Breiger; Emily L Belleau; Marc Normandin; Hans Schroder; Sean Boyden; Emma Hayden; M Taylor Levine; Aava Jahan; Ashley K Meyer; Min Su Kang; Devon Brunner; Steven E Gelda; Jacob Hooker; Georges El Fakhri; Maurizio Fava; Diego A Pizzagalli
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

2.  Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.

Authors:  Michael J Minzenberg; Jong H Yoon; Yaoan Cheng; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2015-09-02       Impact factor: 7.853

Review 3.  Modafinil for people with schizophrenia or related disorders.

Authors:  Javier Ortiz-Orendain; Sergio A Covarrubias-Castillo; Alan Omar Vazquez-Alvarez; Santiago Castiello-de Obeso; Gustavo E Arias Quiñones; Maya Seegers; Luis Enrique Colunga-Lozano
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

4.  Concordant neurophysiological signatures of cognitive control in humans and rats.

Authors:  Mykel A Robble; Hans S Schroder; Brian D Kangas; Stefanie Nickels; Micah Breiger; Ann M Iturra-Mena; Sarah Perlo; Emilia Cardenas; Andre Der-Avakian; Samuel A Barnes; Stefan Leutgeb; Victoria B Risbrough; Gordana Vitaliano; Jack Bergman; William A Carlezon; Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2021-03-21       Impact factor: 8.294

5.  The effect of modafinil on the rat dopamine transporter and dopamine receptors D1-D3 paralleling cognitive enhancement in the radial arm maze.

Authors:  Yasemin Karabacak; Sunetra Sase; Yogesh D Aher; Ajinkya Sase; Sivaprakasam R Saroja; Ana Cicvaric; Harald Höger; Michael Berger; Vasiliy Bakulev; Harald H Sitte; Johann Leban; Francisco J Monje; Gert Lubec
Journal:  Front Behav Neurosci       Date:  2015-08-19       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.